A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc
The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l
Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.
In this episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with André Deschamps, formerly president of Europa Uomo, the voice of men with prostate cancer in Europe.
Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho